The long-term goal of the Shenoy lab is to enable the development of new and innovative therapeutics for pulmonary hypertension, idiopathic pulmonary fibrosis and prostate cancer through better understanding of the molecular mechanisms regulating vascular permeability, angiogenesis, integrin activation, myofibroblast differentiation, extracellular matrix remodeling, oncogenic transformation and bone remodeling. Primary focus of his research is on Transforming growth factor-β (TGFβ), Protein kinase B (Akt) and P21 activated kinases, as well as their signaling partners on mediating these processes.

• Elected as the ‘Fellow of American Heart Association’ (FAHA) - 2013. • Outstanding Achievements in Research Award (2012) at the 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine, Crete, Greece. • Young Investigator Award (2008) at the 12th Biennial Midwest Platelet Conference, University of Kentucky, Lexington, KY. • New Investigator Travel Award (2007) at the 4th Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences, Keystone, CO. • Junior Investigator Award of Excellence (2007) at the Lerner Research Institute staff research retreat, Cleveland Clinic, for the second consecutive year. • Junior Investigator Award of Excellence (2006) at the Lerner Research Institute staff research retreat, Cleveland Clinic. • Irvine H. Page Award (2005) for the best publication at the Department of Molecular Cardiology, Cleveland Clinic. • Innovator Award (2005) by the Cleveland Clinic for the invention of “Novel approach to control vascular maturation and permeability”.